Trials / Recruiting
RecruitingNCT05436093
CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Peking University Cancer Hospital & Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to construct a noninvasive approach 68Ga-ACN376 PET/CT to detect the CLDN18.2 expression of tumor lesions in patients with Solid tumors and to identify patients benefiting from CLDN18.2 targeting treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 18F-FDG | All study participants will undergo one 18F-FDG PET/CT scan. |
Timeline
- Start date
- 2022-06-23
- Primary completion
- 2026-12-01
- Completion
- 2027-12-01
- First posted
- 2022-06-28
- Last updated
- 2026-03-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05436093. Inclusion in this directory is not an endorsement.